Drug
Ficlatuzumab
Ficlatuzumab: highest development phase Phase 3, developed by Aveo Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Aveo Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ficlatuzumab NCT06064877 | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma |
| Ficlatuzumab NCT04100330 | Phase 2 | Acute Myeloid Leukemia |
| Ficlatuzumab NCT02318368 | Phase 2 | Non-small Cell Lung Cancer |
| Ficlatuzumab NCT02109627 | Phase 1 | Acute Myeloid Leukemia |
| Ficlatuzumab NCT02277197 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck |
| Ficlatuzumab NCT02277184 | Phase 1 | Carcinoma, Squamous Cell of Head and Neck |
Latest
Follow Ficlatuzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.